<DOC>
	<DOCNO>NCT02149654</DOCNO>
	<brief_summary>Purpose To characterize safety clinical benefit Engager Transcatheter Aortic Valve Implantation System real world environment . Design Prospective non-randomized , non-interventional , multicenter , single-arm , post-market study . 250 Patients Engager bioprosthesis implant . Patients follow 1 month , 6 month , 12 month procedure . The recruitment period approximately 12 month , total study duration 24 month .</brief_summary>
	<brief_title>Engager Align Post-market Clinical Study</brief_title>
	<detailed_description>The study objective characterize safety clinical benefit Engager Transcatheter Aortic Valve Implantation System real world setting . The primary endpoint study all-cause mortality 30 day index hospitalization . Secondary endpoint study : - Device success accord VARC2 define : - absence procedural mortality ( all-cause mortality discharge , 30 day index hospitalization ) , AND - correct position Engager bioprosthesis proper anatomic location , AND - Engager bioprosthesis perform intend ( prosthesis-patient mismatch mean aortic valve gradient &lt; 20 mmHg peak velocity &lt; 3 m/s , AND moderate severe regurgitation ) . - Composite early safety ( 30 day ) accord VARC2 include following component : - all-cause mortality - stroke - life-threatening bleeding - acute kidney injury ( stage 2-3 ) - coronary artery obstruction require intervention - major vascular complication - valve-related dysfunction require repeat procedure ( BAV , TAVI SAVR ) - Clinical efficacy accord VARC2 6 month 1 year define : - all-cause mortality - stroke - hospitalization valve-related symptom worsen congestive heart failure ( CHF ) - NYHA class III IV - valve-related dysfunction ( mean aortic valve gradient ≥20 mm Hg , effective orifice area ( EOA ) ≤0.9-1.1 cm² and/or Doppler velocity index ( DVI ) &lt; 0.35 m/s , AND/OR moderate severe prosthetic valve regurgitation ) - Time-related valve safety accordingly VARC2 6 month 1 year define : - Structural valve deterioration - Valve-related dysfunction ( mean aortic valve gradient ≥20 mm Hg , ( EOA ) ≤0.9-1.1 cm² and/or ( DVI ) &lt; 0.35 m/s , AND/OR moderate severe prosthetic valve regurgitation ) - Requiring repeat procedure ( TAVI SAVR ) - Prosthetic valve endocarditis - Prosthetic valve thrombosis - Thrombo-embolic event ( e.g . stroke ) - VARC bleeding , unless clearly unrelated valve therapy ( e.g . trauma ) - All-cause mortality 6 month 1 year - Cardiovascular mortality 30 day , 6 month 1 year - Incidence TAVI-related complication 30 day , 6 month 1 year : - Myocardial infarction - Periprocedural spontaneous stroke - Life-threatening , major minor bleeding - Acute kidney injury state 1 , 2 3 - Apical vascular complication - Conduction disturbance - Conversion open-heart surgery - Unplanned use cardiopulmonary bypass - Coronary obstruction dissection - Ventricular septal perforation - Mitral valve apparatus damage dysfunction - Cardiac tamponade - Endocarditis - Valve thrombus - Valve migration , embolization ectopic valve deployment - Valve valve deployment - Total , transvalvular paravalvular regurgitation measure TTE 30 day 1 year - Mean aortic valve gradient , peak velocity effective orifice area measure TTE 30 day 1 year - Engager implant depth measure standard care angiography end implant procedure - Incidence rationale permanent pacemaker implantation Engager implant procedure - Changes Quality Life measure EQ5D questionnaire baseline , discharge , 30 day , 6 month 1 year - Length stay index hospitalization ( ICU general ward ) - Incidence re-hospitalization 30 day , 6 month 1 year Subject population All patient severe aortic stenosis require treatment , select heart team treat electively Engager Transcatheter Aortic Valve Implantation System eligible include study . Treatment The Engager Transcatheter Aortic Bioprosthesis implant use Engager Transcatheter Delivery System . The bioprosthesis deliver transapically catheter beat heart procedure .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Patient include ALL follow criterion meet : Patient severe aortic valve stenosis require treatment ; Patient acceptable candidate elective treatment Medtronic Engager Transcatheter Aortic Valve Implantation System conformity local regulatory requirement ; Patient minimum age require local regulation participate clinical study ; The patient inform nature study consent participate , authorize collection release his/her medical information sign consent form ( Patient Informed Consent Form Data Release Form ) . Patient include follow condition exist : Known hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , Nitinol contrast medium adequately controlled premedication ; Intracardiac mass , thrombus , vegetation ; Aortic aneurysm ; Sepsis acute endocarditis ; Bleeding diathesis , coagulopathy ; Cardiogenic shock , suspect cardiogenic shock ; Unicuspid bicuspid aortic valve ; Preexisting prosthetic heart valve aortic position ; Patient currently enrol another investigational device drug trial ; Patients life expectancy le 12 month TAVI .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Transcatheter aortic valve implantation</keyword>
	<keyword>Transcatheter aortic valve replacement</keyword>
	<keyword>Engager transcatheter aortic valve implantation system</keyword>
	<keyword>Engager bioprosthesis</keyword>
</DOC>